BioXcel Therapeutics
(NASDAQ) BTAI
BioXcel Therapeutics Financials at a Glance
Market Cap
$25.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$680.00K
Net Income (TTM)
-$75.33M
EPS (TTM)
-$6.19
P/E Ratio
-0.13
Dividend
$0.00
Beta (Volatility)
1.62 (High)
Dividend
$0.00
Beta (Volatility)
1.62 (High)
Price
$0.83
Volume
712,109
Open
$0.83
Price
$0.83
Volume
712,109
Open
$0.83
Previous Close
$0.82
Daily Range
$0.79 - $0.87
52-Week Range
$0.74 - $8.08
Estimated Earnings Date
Aug 11, 2026
Dividend
$0.00
Beta (Volatility)
1.62 (High)
Price
$0.83
Volume
712,109
Open
$0.83
Previous Close
$0.82
Daily Range
$0.79 - $0.87
52-Week Range
$0.74 - $8.08
Estimated Earnings Date
Aug 11, 2026
BTAI News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout BioXcel Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
29
CEO
Vimal D. Mehta, PhD
Website
www.bioxceltherapeutics.comHeadquarters
New Haven, CT 06511, US
BTAI Financials
Key Financial Metrics (TTM)
Gross Margin
27.79%
Operating Margin
-7395.00%
Net Income Margin
-11078.53%
Return on Equity
75.79%
Return on Capital
-354.09%
Return on Assets
-221.41%
Earnings Yield
-7.69%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$25.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
30.88M
Volume
712.11K
Avg. Volume
930.62K
Financials (TTM)
Gross Profit
$189.00K
Operating Income
-$50.29M
EBITDA
-$57.86M
Operating Cash Flow
-$57.38M
Capital Expenditure
$0.00
Free Cash Flow
-$57.38M
Cash & ST Invst.
$17.18M
Total Debt
$100.29M
BioXcel Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$206.00K
+22.6%
Gross Profit
-$135.00K
-187.7%
Gross Margin
-65.53%
N/A
Market Cap
$25.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$870.43K
N/A
Employees
29
N/A
Net Income
-$12.69M
-75.0%
EBITDA
-$8.44M
-164.8%
Quarterly Fundamentals
Total Cash
$17.18M
-44.6%
Total Debt
$100.29M
-5.3%
Accounts Receivable
$216.00K
N/A
Inventory
$500.00K
-22.1%
Long Term Debt
$77.86M
-22.1%
Short Term Debt
$22.43M
+276.5%
Return on Assets
-2.21%
N/A
Return on Invested Capital
2.40%
N/A
Free Cash Flow
-$11.81M
+1.9%
Operating Cash Flow
-$11.81M
+1.9%